Market Overview

The North American continuous glucose monitoring (CGM) market is experiencing robust growth, driven by the increasing prevalence of diabetes, technological advancements, and rising demand for more precise and patient-friendly solutions. Continuous glucose monitoring systems allow individuals with diabetes to track their blood sugar levels in real-time without the need for frequent finger pricks. This innovative technology is revolutionizing diabetes management, providing patients and healthcare providers with more reliable and real-time data to make informed decisions regarding insulin administration and lifestyle changes.

As the incidence of diabetes rises in North America and more people seek advanced solutions for monitoring their condition, the demand for CGM systems continues to grow. The market was valued at USD 6.56 billion in 2024 and is expected to witness significant expansion, reaching USD 23.22 billion by 2034. This growth is largely attributed to innovations in CGM technology, increasing consumer awareness, and the growing adoption of home healthcare devices. The market is projected to grow at a compound annual growth rate (CAGR) of 14.5% from 2025 to 2034.

Market Size and Share

In 2024, the North American CGM market was valued at USD 6.56 billion. The increasing prevalence of diabetes, coupled with new product developments, continues to fuel market growth. By 2025, the market is expected to grow to USD 7.51 billion and reach USD 23.22 billion by 2034, driven by technological innovations and the increasing shift towards home healthcare. The market's expected CAGR of 14.5% reflects the growing demand for real-time monitoring solutions that offer better control over blood glucose levels.

The United States dominates the North American CGM market due to its high prevalence of diabetes, well-established healthcare infrastructure, and extensive adoption of advanced diabetes management devices. Canada also plays a significant role, though its market share is smaller compared to the U.S.

Get  a free sample request: https://www.expertmarketresearch.com/reports/north-america-continuous-glucose-monitoring-market/requestsample

Market Trends

Technological Advancements in CGM Systems

Technological advancements are transforming the CGM landscape. New-generation sensors, transmitters, and receivers are becoming more accurate, durable, and user-friendly. These innovations allow patients to receive real-time, continuous glucose data, which improves their ability to manage diabetes. The integration of CGM systems with mobile apps, smartphones, and other digital health tools further enhances user experience, allowing for better data analysis and sharing with healthcare providers.

Shift to Home Healthcare

The shift towards home healthcare has accelerated the adoption of CGM systems. Patients with diabetes can now monitor their blood glucose levels conveniently from home, reducing the need for frequent doctor visits. This trend has been further fueled by the COVID-19 pandemic, which highlighted the importance of remote patient monitoring. Home healthcare solutions are now more affordable, and their ease of use continues to drive adoption, especially among individuals with Type 1 and Type 2 diabetes.

Increasing Prevalence of Diabetes

The rising prevalence of diabetes in North America is a significant driver of the CGM market. According to the Centers for Disease Control and Prevention (CDC), over 37 million Americans suffer from diabetes, and this number is expected to increase. As diabetes cases continue to rise, the need for advanced monitoring solutions such as CGM systems will only continue to grow. Early diagnosis and consistent monitoring are essential to managing the disease and preventing complications.

Regulatory Approvals and Insurance Coverage Expansion

The approval of new CGM systems by regulatory bodies, including the U.S. Food and Drug Administration (FDA), has positively impacted the market. Additionally, the expansion of insurance coverage for diabetes management tools, including CGM systems, has improved accessibility and affordability. With more insurance providers offering coverage for CGM devices, the adoption rate of these systems is expected to rise significantly, especially among patients with Type 1 and Type 2 diabetes.

Market Analysis

Scope of the Report

This report provides a comprehensive analysis of the North American CGM market, focusing on its components, applications, end users, and regional segmentation. It covers historical trends, current market dynamics, and forecasts for market growth. The analysis of various segments, including sensors, transmitters, and receivers, as well as the application areas such as Type 1 and Type 2 diabetes, provides valuable insights for stakeholders to make informed decisions.

Historical and Forecast Trends

The North American CGM market has seen significant growth over the past decade. From a niche technology to a mainstream solution for diabetes management, CGM systems have gained widespread acceptance. The market is projected to continue its upward trajectory, with a forecasted CAGR of 14.5% from 2025 to 2034. Key drivers include the technological advancements in CGM devices and the rising demand for diabetes management solutions.

Industry Drivers and Constraints

The key drivers of the CGM market include the increasing incidence of diabetes, technological advancements in CGM systems, and the rising demand for home healthcare solutions. However, the market faces certain constraints, including the high cost of CGM devices, limited insurance coverage in some regions, and the need for further regulatory approvals for new products. Overcoming these challenges will be crucial for the continued expansion of the CGM market.

Historical and Forecast Market Analysis by Segment

• Components: The major components of CGM systems include sensors, transmitters, and receivers. Sensors play a crucial role in detecting glucose levels in the interstitial fluid, transmitters relay this data to the receiver, and the receiver displays the glucose readings for the user.
• Application: CGM systems are widely used for the management of Type 1 and Type 2 diabetes. In addition, CGMs are also gaining traction in managing gestational diabetes and other medical conditions where glucose monitoring is essential.

Regional Insights

United States

The United States dominates the North American CGM market, with a significant share of the global market. Factors driving this growth include the high prevalence of diabetes, strong healthcare infrastructure, and a large number of players operating in the region. The demand for CGM systems is particularly strong in the U.S. due to the increasing adoption of home healthcare solutions and the growing awareness of diabetes management tools.

Canada

Canada is also experiencing steady growth in the CGM market, albeit at a smaller scale compared to the U.S. The Canadian government has been actively supporting diabetes care initiatives, and the country has seen increasing adoption of CGM systems, especially among patients with Type 1 diabetes. The availability of insurance coverage for diabetes management tools has played a key role in driving the demand for CGMs in Canada.

Market Growth

The market for continuous glucose monitoring in North America is expected to grow at a rapid pace between 2025 and 2034, driven by several factors. The rising prevalence of diabetes, especially among the adult population, combined with the growing demand for home healthcare solutions, will continue to fuel the market. Moreover, innovations in CGM technology, such as improved sensors, smaller devices, and real-time data analysis, will make these devices even more appealing to users.

As healthcare systems move towards more patient-centered care, the demand for CGMs will grow, particularly in home healthcare settings. Additionally, regulatory approvals and expanded insurance coverage will provide further impetus for the adoption of CGM devices.

Recent Developments & Challenges

Technological Advancements

Recent technological advancements in CGM systems have made them more accurate, reliable, and easier to use. New sensors provide longer-lasting glucose readings, and wireless technology allows for seamless integration with mobile apps and cloud-based platforms. These advancements are expected to drive increased adoption rates among consumers.

Regulatory Approvals

The FDA has approved several new CGM devices in recent years, contributing to market growth. These approvals provide patients with more options and offer improved accuracy and functionality in managing their blood glucose levels.

Expansion of Insurance Coverage

Insurance coverage for diabetes management tools, including CGM systems, is expanding in the United States and Canada. This has made CGMs more affordable for patients, particularly those with Type 1 and Type 2 diabetes, thereby driving adoption.

High Cost and Accessibility

The high cost of CGM systems remains a challenge. Although insurance coverage is expanding, many patients still find the out-of-pocket costs prohibitive. Reducing the cost of devices and increasing insurance coverage will be key to making CGMs more accessible to a larger portion of the population.

Key Players

Abbott

Abbott is one of the leading players in the CGM market, known for its FreeStyle Libre system, which has become widely adopted for managing diabetes. Abbott’s continuous glucose monitoring systems are renowned for their accuracy, ease of use, and affordability. The company is at the forefront of innovation in CGM technology, constantly improving sensor performance and reducing the size of devices to enhance user experience.

Dexcom, Inc.

Dexcom is a global leader in the continuous glucose monitoring market, offering products like the Dexcom G6 and G7 CGM systems. Dexcom's devices are known for their high precision, real-time data sharing capabilities, and integration with mobile apps. The company continues to innovate in CGM technology, focusing on improving sensor accuracy, minimizing user intervention, and enhancing connectivity.

Medtronic PLC

Medtronic is a major player in the diabetes care market, offering CGM systems alongside its insulin pumps and other diabetes management tools. Medtronic’s Guardian Connect CGM system is widely used by patients with diabetes, providing real-time glucose monitoring and alerts. The company is committed to improving patient care through innovations in CGM technology.

Senseonics, Inc.

Senseonics specializes in implantable CGM systems, offering the Eversense CGM system. Unlike traditional CGMs, Eversense is implanted under the skin, providing up to 90 days of continuous glucose monitoring. This technology offers patients an alternative to traditional, sensor-based CGMs, providing longer-lasting monitoring with minimal user intervention.

Other notable companies in the North American CGM market include Byram Healthcare Centers, Inc., Hoffmann-La Roche Limited, and Abbott Laboratories.

FAQs

What is Continuous Glucose Monitoring (CGM)?

CGM is a technology that tracks glucose levels in real-time throughout the day and night, offering patients with diabetes an accurate way to manage their blood sugar levels continuously.

What are the components of CGM systems?

The main components of CGM systems include sensors, transmitters, and receivers. Sensors detect glucose levels, transmitters send the data to the receiver, and the receiver displays the results.

 Why are CGM systems so important for diabetes management?

CGM systems provide continuous, real-time glucose data, which helps patients make timely decisions regarding insulin use and dietary changes, improving overall blood sugar control and reducing complications.

What are the primary applications of CGMs?

CGMs are primarily used for managing Type 1 and Type 2 diabetes, as well as gestational diabetes and other conditions that require constant blood glucose monitoring.

More Related Report: 

Top 7 Spectrophotometer Companies in the Global Market
Top 8 Viral Inactivation Firms
Global Vessel Sealing Device Market
India Healthcare Investment Surge